Opinion|Videos|September 9, 2024
Looking Beyond Type 2 Inflammation in Atopic Dermatitis
Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With better understanding of the pathophysiology of atopic dermatitis, how important is to look beyond type 2 inflammation?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5